Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Scandion Oncology

0.017

 

SEK

 

-2.94 %

Less than 1K followers

SCOL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Compare
-2.94%
-68.27%
-77.85%
-80.24%
-88.78%
-97.58%
-99.63%
-99.48%
-99.3%

Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.

Read more
Market cap
3.87M SEK
Turnover
44.17K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
12.3.
2025

Annual report '24

29.4.
2025

General meeting '25

22.5.
2025

Interim report Q1'25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.